Ecofucin® is a fixed-dose combination (FDC) vaginal suppository containing Natamycin (antifungal) + Lactulose (prebiotic), providing faster onset of action, symptom relief, and restoration of the vaginal flora.
Natamycin is highly effective against *Candida spp.* and superior vs azole-resistant strains, positioning it as a key option for azole-resistant infections.
Lactulose promotes beneficial bacteria growth, reinforcing natural competitive inhibition of pathogenic microorganisms — delivering infection management and eubiosis restoration.
Key Features
● Dual action: infection management + eubiosis restoration
● Potent antifungal effective against azole-resistant strains
● Faster clinical remission vs Natamycin monotherapy
● Restores and maintains vaginal microflora
● Prophylactic use post-surgery and in early pregnancy
Clinical Profile
● Patent protected — US patent US20110202025A1
● Global VVC market: US$ 1,035 M (2023) → US$ 1,607 M by 2033 (CAGR 4.5%)
● 81.6% clinical recovery at Day 7 vs 62.3% Pimafucin® (Volkova et al. 2025, n=218)
● 90.8% mycological recovery at Day 37; superior vaginal Lactobacillus restoration
● Competitive inhibition provides protection from reinfection
Key Conclusions — Volkova et al. 2025
1. 81.6% clinical recovery at Day 7 with Ecofucin® DUO vs 62.3% Pimafucin® vs 42.9% Lactulose (p<0.001) — largest RCT to date in acute VVC (n=218).
2. 90.8% mycological eradication at Day 37 confirms durable fungal eradication and sustained treatment effect.
3. Superior vaginal microflora restoration (Lactobacillus normalization) at Day 37 — reducing recurrence risk and supporting long-term vaginal health.
4. Patent-protected formulation (US20110202025A1) in a growing global VVC market projected to reach US$ 1.607 billion by 2033 (CAGR 4.5%).
